Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial

• Published in: Skin research and technology Vol. 30; no. 4; pp. e13689 - n/a
• Main Authors: Mohammadi, Farhad, Harofteh, Fatemeh Zare, Sahebnasagh, Adeleh, Ghaneei, Narges, Ardakani, Mohammad Ebrahim Zadeh, Saghafi, Fatemeh
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01-04-2024; John Wiley and Sons Inc
• Subjects: clinical trial; Clinical trials; Dermatology; Effectiveness; Erythema; Immunomodulation; Inflammation; Melatonin; Original; Oxidants; Oxidizing agents; Pathogenesis; Placebos; Population studies; Psoriasis; Quality of life; rosuvastatin; Safety; Skin diseases; clinical trial; melatonin; rosuvastatin; psoriasis
• DOI: 10.1111/srt.13689
• EISSN: 1600-0846
• ISSN: 0909-752X

Background
Considering the pathogenesis of psoriasis and also the anti‐oxidant, immunomodulatory, and anti‐inflammatory properties of rosuvastatin and melatonin, the current clinical trial aimed to evaluate the efficacy of topical rosuvastatin and melatonin in patients with mild to moderate psoriasis.
Methods
The current randomized placebo‐controlled clinical trial was conducted using a 3‐arm parallel group included 77 adult patients (≥18 years old) with mild to moderate plaque psoriasis.
Patients were randomized into a 1:1:1 ratio to one of three groups to receive one of the three interventions: melatonin cream, 5.0% (w/w), rosuvastatin cream, 5.0% (w/w), or placebo cream with a similar transparent appearance twice a day for 12 weeks. The primary outcome was severity of the disease using Psoriasis Area Severity Index (PASI). The secondary outcomes included the Dermatological Sum Score (DSS) to assess the erythema, scaling, and plaque elevation and the Dermatology Life Quality Index (DLQI). Photographs of the lesions were also taken at the baseline and at different periodic intervals thereafter.
Results
Among 77 randomized patients, 52 (mean (SD) age, 40.67 (10.85) years; 22 (42.30%) men) completed the study. A significant reduction of 45% (mean (SD) of 2.67 (0.98) to 1.74 (1.12)) and 70% (mean (SD) of 2.67 (0.98) to 1.31 (1.13)) in PASI score, and 46% (mean (SD) of 2.91(1.85) to 1.57 (1.11)) and 77% (mean (SD) of 2.91 (1.85) to 0.87 (0.67)) in DSS score on days 30 and 60 with rosuvastatin cream, 5% w/w (P < 0.001) compared with baseline was observed, respectively.
Also a significant decrease of 35% (mean (SD) of 2.67 (0.98) to 1.74 (1.12)) and 51% (mean (SD) of 2.67 (0.98) to 1.31 (1.13)) in PASI score, and 40% (mean (SD) of 5.00 (1.58) to 3.00 (1.76))and 61% (mean (SD) of 5.00 (1.58) to 1.92 (1.71)) in DSS score on days 30 and 60 with melatonin cream, 5% w/w (P < 0.001) compared with baseline were observed, respectively. In each of the melatonin or rosuvastatin groups, DLQI improved significantly on days 30 (P < 0.0001) and 60 (P < 0.001) while the changes in the control group were not significant.
Conclusion
The results of this clinical trial demonstrated that topical melatonin and rosuvastatin diminished the severity of mild to moderate plaque psoriasis with a satisfactory safety profile. Future clinical trials should assess both the long‐term efficacy and safety of melatonin and rosuvastatin creams in larger study populations.